Literature DB >> 3874014

Determination of C1s-C1 inhibitor complexes in plasma by means of an enzyme linked immunosorbent assay.

T Nilsson, O Bäck.   

Abstract

An enzyme linked differential antibody immunosorbent assay for the quantitation of the C1s-C1 inhibitor complex has been developed. A study of the assays' performance under various conditions has shown that before use in the assay, it is imperative to remove competing forms of C1s from the samples to be tested. This is conveniently achieved in human plasma or serum by polyethylene glycol precipitation of the C1qrs, since the C1s-C1 inhibitor complex remains soluble and can be assayed in the supernatant solution. The detection limit of the assay in the plasma milieu is 0.1 mg/l, and the concentrations of the C1s-C1 inhibitor complex were found to be 1 mg/l in citrated plasma and 2 mg/l in serum. Activation of the fibrinolytic system in vivo does not seem to result in any appreciable C1 activation, since there was no concomitant major change in the plasma concentration of the C1s-C1 inhibitor complex.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874014      PMCID: PMC1576998     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  C1 subcomponent conplexes in normal and pathological sera studied by crossed immunoelectrophoresis.

Authors:  A B Laurell; U Mårtensson; A G Sjöholm
Journal:  Acta Pathol Microbiol Scand C       Date:  1976-12

2.  Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors.

Authors:  D Collen
Journal:  Thromb Res       Date:  1974-12       Impact factor: 3.944

3.  Inability of a highly purified streptokinase preparation to inactivate complement in serum.

Authors:  A B Laurell; B Lundh; J Malmquist
Journal:  Acta Pathol Microbiol Scand       Date:  1965

4.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Authors:  B Ghebrehiwet; B P Randazzo; J T Dunn; M Silverberg; A P Kaplan
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

5.  Studies on the first component of complement (C1) and the inhibitor of C1 esterase in rheumatoid synovial fluids.

Authors:  M M De Bracco; R M Stroud; C L Christian
Journal:  Clin Exp Immunol       Date:  1972-06       Impact factor: 4.330

6.  Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s.

Authors:  T Nilsson; B Wiman
Journal:  Eur J Biochem       Date:  1983-01-01

7.  A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo.

Authors:  C E Hack; A J Hannema; A J Eerenberg-Belmer; T A Out; R C Aalberse
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

8.  Purification and characterization of human C1-esterase inhibitor.

Authors:  T Nilsson; B Wiman
Journal:  Biochim Biophys Acta       Date:  1982-07-26

9.  Activation of factor XII by dextran sulfate: the basis for an assay of factor XII.

Authors:  D L Tankersley; B M Alving; J S Finlayson
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

10.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

View more
  4 in total

1.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  Measurement of complement activation products in patients with chronic rheumatic diseases.

Authors:  G Auda; E R Holme; J E Davidson; A Zoma; J Veitch; K Whaley
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

Review 4.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.